Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer

PharmacoEconomics

Volumn 30, Issue 2, 2012, Pages 103-118

  Griffiths, Robert I ^a,b   Barron, Richard L ^c   Gleeson, Michelle L ^a   Danese, Mark D ^a   Ohagan, Anthony ^d   Chia, Victoria M ^c   Legg, Jason C ^c   Lyman, Gary H ^e  

^a Outcomes Insights Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e DUKE CANCER INSTITUTE   (United States)

Author keywords

Anthracyclines; Chemotherapy induced anaemia; Cost analysis; Cyclophosphamide; Early breast cancer; Fluorouracil; Granulocyte colony stimulating factors; Taxanes.

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; COST OF ILLNESS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MULTIPLE CYCLE TREATMENT; NATIONAL CANCER INSTITUTE COMORBIDITY INDEX; NEUTROPENIA; PRIORITY JOURNAL; SCORING SYSTEM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTINENTAL POPULATION GROUPS; COSTS AND COST ANALYSIS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEAST-SQUARES ANALYSIS; LONG-TERM CARE; MEDICARE; NEUTROPENIA; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84855892258     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11589440-000000000-00000     Document Type: Article

References (43)

1. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42 (15): 2433-53 (Pubitemid 44442936)
2. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19): 3187-205 (Pubitemid 46638957)
3. National Comprehensive Cancer Network. Practice guide- lines in oncology v.1.2010: myeloid growth factors [online]. Available with user ID and password from URL: http://www.nccn.org/professionals/physician-gls/PDF/myeloid- growth.pdf. [Accessed 2010 Oct 1]
4. Greil R, Psenak O, Roila F. Hematopoietic growth factors: ESMO recommendations for the applications. Ann Oncol 2008; 19 Suppl. 2: ii116-8
5. Carrato A, Paz-Ares Rodriguez L, Rodriguez Lescure A, et al. Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients. Clin Transl Oncol 2009; 11 (7): 446-54
6. Aapro M, Crawford J, Kamioner D. Prophylaxis of che- motherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 2010; 18 (5): 529-41
7. Martin M, Lluch A, Segui MA, et al. Toxicity and health- related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte colony stimulating factor to the TAC regimen. Ann Oncol 2006; 17 (8): 1205-12 (Pubitemid 44288210)
8. von Minckwitz G, Kummel S, du Bois A, et al. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/ cyclophosphamide) chemotherapy for breast cancer: results from the GEPARTRIO study. Ann Oncol 2008; 19 (2): 292-8 (Pubitemid 351201710)
9. Piedbois P, Serin D, Priou F, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007; 18 (1): 52-7 (Pubitemid 46152499)
10. Wildiers H, Dirix L, Neven P, et al. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence. Breast Cancer Res Treat 2009; 114 (1): 103-12
11. Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2007; 87 (4): 277-83
12. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995; 332 (14): 901-6
13. Lee KW, Kim DY, Yun T, et al. Doxorubicin-based che- motherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxo-rubicin dosage. Cancer 2003; 98 (12): 2651-6 (Pubitemid 37509529)
14. Kwak LW, Halpern J, Olshen RA, et al. Prognostic sig- nificance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8 (6): 963-77 (Pubitemid 20200184)
15. Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009; 114 (3): 479-84
16. Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008; 87 (5): 429-30
17. Earl HM, Hiller L, Dunn JA, et al. NEAT: National Epirubicin Adjuvant Trial: toxicity, delivered dose intensity and quality of life. Br J Cancer 2008; 99 (8): 1226-31
18. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008; 100 (9): 630-41
19. Stokes ME, Thompson D, Montoya EL, et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 2008; 11 (2): 213-20 (Pubitemid 351473603)
20. Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11 (2): 172-9 (Pubitemid 351473616)
21. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009; 7 (1): 99-108
22. Warren JL, Brown ML, Fay MP, et al. Costs of treatment for elderly women with early-stage breast cancer in fee-forservice settings. J Clin Oncol 2002; 20 (1): 307-16 (Pubitemid 34032626)
23. National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat database: Incidence-SEER 17 Regs Limited-Use+Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973-2006 varying)-Linked To County Attributes-Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2009, based on the November 2008 submission [online]. Available from URL: http://www.seer.can cer.gov [Accessed 2010 Jun 1]
24. National Cancer Institute. SEER-Medicare: how the SEER & Medicare data are linked. Bethesda (MD): National Cancer Institute, 2010 [online]. Available from URL: http://healthservices.cancer.gov/seermedicare/overview/ linked. html [Accessed 2010 May 25]
25. Klabunde CN, Legler JM, Warren JL, et al. A refined co- morbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007; 17 (8): 584-90 (Pubitemid 47096709)
26. Fritz A, Ries L, eds. The SEER program code manual. 3rd ed. Bethesda (MD): Cancer Statistics Branch, Surveillance Program, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Public Health Service, US Dept of Health and Human Services, 1998 [online]. Available from URL: http://seer.cancer.gov/manuals/codeman.pdf [Accessed 2010 Oct 5]
27. National Cancer Institute: Health Services and Economics- SEER-Medicare Programming Support. 2010 [online]. Available from URL: http://healthservices. cancer.gov/seermedicare/program/remove.ruleout.dxcodes.macro.txt [Accessed 2010 Aug 27]
28. National Cancer Institute: Health Services and Economics- SEER-Medicare Programming Support (Charlson Co-morbidity). 2010 [online]. Available from URL: http://healthservices.cancer.gov/seermedicare/program/charlson. comorbidity.macro.txt [Accessed 2010 Aug 27]
29. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-83 (Pubitemid 17055592)
30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical co- morbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45 (6): 613-9
31. Romano PS, Roos LL, Luft HS, et al. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol 1994; 47 (3): 249-60 (Pubitemid 24109737)
32. National Comprehensive Cancer Network. NCCN guide- lines for patients: breast cancer. Fort Washington (PA): NCCN [online]. Available from URL: http://www.nccn. com/images/patient-guidelines/pdf/breast.pdf [Accessed 2010 Oct 5]
33. Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika 2000; 87 (2): 329-43
34. Lin DY. Linear regression analysis of censored medical costs. Biostatistics 2000; 1 (1): 35-47
35. Efron B, Tibshirani RJ. An introduction to the bootstrap (monographs on statistics and applied probability). Boca Raton (FL): Chapman & Hall/CRC, 1994
36. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365 (9472): 1687-717
37. Siegel J. FDA approval letter: pegfilgrastim. Rockville (MD) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4185B1- 03-08-FDA-Tab5a.pdf [Accessed 2010 Oct 5]
38. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 (4785): 177-82 (Pubitemid 17231334)
39. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007; 357 (1): 39-51 (Pubitemid 47026733)
40. National Cancer Institute. FDA approval for trastuzumab. Bethesda (MD): NCI, 2010 [online]. Available from URL: http://www.cancer.gov/cancertopics/ druginfo/fda-trastuzu mab [Accessed 2010 Oct 5]
41. Basu A, Manning WG. Estimating lifetime or episode- of-illness costs under censoring. Health Econ 2010; 19 (9): 1010-28
42. Imbens GW. Nonparametric estimation of average treatment effects under exogeneity: a review. Rev Econ Stat 2004; 86 (1): 4-29 (Pubitemid 38422764)
43. Cattaneo MD, Crump RK, Jansson M. Bootstrapping density-weighted average derivatives. Federal Reserve Bank of New York Staff Reports 2010 May; 452